Supplement: Cardiology and Therapy by unknown
COMMENTARY
Supplement: Cardiology and Therapy
Alejandro de la Sierra
To view enhanced content go to www.cardiologytherapy-open.com
Received: May 29, 2015 / Published online: June 19, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
INTRODUCTION
Ambulatory blood pressure monitoring (ABPM)
is a tool of great value for the diagnosis and
monitoring of hypertensive patients. Its
principal advantages are, on the one hand,
obtaining a greater number of measures in an
environment closer to the individual’s daily life,
that better reflect the individual’s real blood
pressure, and, on the other hand, a better
correlation with organ damage and
cardiovascular prognosis [1]. ABPM is
envisaged as a complementary tool in all
clinical guidelines for treating hypertension
and, in some cases, is obligatory for
confirmation of the diagnosis [2, 3].
The role of ABPM is not limited to the
diagnosis of patients, but also constitutes a
useful element in the assessment of treatment
and in clinical monitoring [4]. The principal
mean estimators during the 24 h over which the
monitoring is usually performed, such as the
two periods of activity (usually during the
daytime) and of rest (usually at night), are
prognostically important and enable the impact
of the treatment to be targeted more precisely.
Furthermore, differences with clinical
measurement that result in the phenotypes of
white-coat hypertension and masked
hypertension enable treatment response to be
better defined and allow the identification of
patients who will require a different therapeutic
approach [5, 6].
In addition to these mean estimators, the so-
called ‘‘estimators of variability’’, which reflect
the fluctuations in blood pressure over a 24-h
period, are gaining ever greater attention.
Among these, the nocturnal drop in blood
pressure and the standard deviations during
the diurnal and nocturnal periods can be
highlighted. There are also indicators that
provide information on the effects of
medication on monitoring, such as the
trough-to-peak ratio, the smoothness index or
the treatment-on-variability index [7].
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All these variables proposed as diagnostic
assessment indexes, and more specifically in
assessing treatment, have been evaluated in
various controlled studies in which the basis of
antihypertensive treatment has been the
angiotensin-receptor antagonist olmesartan. It
has been observed in these studies that
olmesartan and combinations of this drug
with the calcium-channel blocker amlodipine,
the diuretic hydrochlorothiazide or both, are
able to reduce blood pressure over 24 h, diurnal
and nocturnal, achieving high levels of
ambulatory control [8].
Controlled clinical trials also show that
treatment with olmesartan and its
combinations has a duration of effect that
covers the 24-h period, does not affect the
circadian rhythm or nocturnal rest, regardless of
whether it is administered in the morning or
the evening, and effectively reduces morning
blood pressure and the morning rise in blood
pressure, parameters that are both related to
cardiovascular and cerebrovascular prognosis
[9, 10].
Other studies also show a reduction in the
day-to-day variability of blood pressure, which
is associated with effects such as arterial rigidity
[11].
This accumulation of evidence about the
pharmacological effects on ambulatory blood
pressure, both mean estimators and estimators
of variability, is a major step forward in the
understanding of the action of antihypertensive
drugs or procedures. It is to be expected that, in
the future, changes in these estimators as
assessed in clinical research will have a
fundamental role in the selection of the most
appropriate treatment(s) for hypertensive
patients.
ACKNOWLEDGMENTS
This supplement has been sponsored by
Menarini. The named author meets the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
manuscript, takes responsibility for the integrity
of the work as a whole, and has given final
approval for the version to be published.
Conflict of interest. Alejandro De la Sierra
declares honoraria for participation in scientific
meetings funded by Abbott, Daiichi-Sankyo,
Lacer, Menarini, Merck, Sharp and Dohme,
and Pfizer.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. O’Brien E, Parati G, Stergiou G, et al. European
Society of Hypertension position paper on
ambulatory blood pressure monitoring.
J Hypertens. 2013;31:1731–68.
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/
ESC Guidelines for the management of arterial
hypertension. The Task Force for the management
of arterial hypertension of the European Society of
Hypertension (ESH) and of the European Society of
Cardiology (ESC). J Hypertens. 2013;31:1281–357.
3. National Institute for Health and Clinical
Excellence (NICE). Hypertension. The clinical
management of primary hypertension in adults.
Clinical Guideline 127. 2011. http://www.nice.org.
uk/guidance/CG127.
S2 Cardiol Ther (2015) 4 (Suppl 1):S1–S3
4. Mancia G, Parati G. Office compared with
ambulatory blood pressure in assessing response to
antihypertensive treatment: a meta-analysis.
J Hypertens. 2004;22:435–45.
5. Vinyoles E, Felip A, Pujol E, et al. Clinical
characteristics of isolated clinic hypertension.
J Hypertens. 2008;26:438–45.
6. Banegas JR, Ruilope LM, de la Sierra A, et al. High
prevalence of masked uncontrolled hypertension
(MUCH) in people with treated hypertension. Eur
Heart J. 2014;35:3304–12.
7. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment
and management of blood-pressure variability. Nat
Rev Cardiol. 2013;10:143–55.
8. Izzo JL Jr, Chrysant SG, Kereiakes DJ, et al. 24-hour
efficacy and safety of triple-combination therapy
with olmesartan, amlodipine, and
hydrochlorothiazide: the TRINITY ambulatory
blood pressure substudy. J Clin Hypertens
(Greenwich). 2011;13:873–80.
9. Kario K, Saito I, Kushiro T, et al. Effect of the
angiotensin II receptor antagonist olmesartan on
morning home blood pressure in hypertension:
HONEST study at 16 weeks. J Hum Hypertens.
2013;27:721–8.
10. Mori H, Yamamoto H, Ukai H, COMPATIBLE Study
Group, et al. Comparison of effects of angiotensin II
receptor blocker on morning home blood pressure
and cardiorenal protection between morning
administration and evening administration in
hypertensive patients: the COMPATIBLE study.
Hypertens Res. 2013;36:202–7.
11. Matsui Y, O’Rourke MF, Hoshide S, Ishikawa J,
Shimada K, Kario K. Combined effect of
angiotensin II receptor blocker and either a
calcium channel blocker or diuretic on day-by-day
variability of home blood pressure: the Japan
Combined Treatment with Olmesartan and a
Calcium-Channel Blocker Versus Olmesartan and
Diuretics Randomized Efficacy Study.
Hypertension. 2012;59:1132–8.
Cardiol Ther (2015) 4 (Suppl 1):S1–S3 S3
